LIFEMD, INC v. LAMARCO

CourtDistrict Court, W.D. Pennsylvania
DecidedJune 13, 2022
Docket2:21-cv-01273
StatusUnknown

This text of LIFEMD, INC v. LAMARCO (LIFEMD, INC v. LAMARCO) is published on Counsel Stack Legal Research, covering District Court, W.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LIFEMD, INC v. LAMARCO, (W.D. Pa. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA

LIFEMD, INC. et al, Plaintiffs, Civil Action No, 2:21-cv-1273 v. Hon. William S. Stickman IV CHRISTIAN MATTHEW LAMARCO, et al, Defendants.

MEMORANDUM OPINION WILLIAM S. STICKMAN IV, United States District Judge Plaintiffs LifeMD, Inc. (“LifeMD”), Justin Schreiber (“Schreiber”), and Stefan Galluppi (“Galluppi”), filed an eight-count Complaint against Defendants Christian Matthew Lamarco (“Lamarco”), Shadyside Partners, LLC d/b/a Culper Research! (“Culper”) and John/Jane Does 2- 10 (“John Does”) in the Court of Common Pleas of Allegheny County, Pennsylvania on September 17, 2021, asserting defamation (Count I), trade libel (Count IJ), false light (Count IID, unjust enrichment (Count IV), deceptive trade practices (Count V), unfair competition (Count VD), conspiracy (Count VID and aiding and abetting (Count VIII).? (ECF No. 1-2). On September 23, 2021, Lamarco and Culper removed the case to the United States District Court for the Western District of Pennsylvania pursuant to 28 U.S.C. § 1332. (ECF No. 1). Lamarco and Culper then moved for the dismissal of Counts I through VII under Federal Rule of Civil Procedure 12(b)(6)

' Christian Matthew Lamarco is the sole employee and member of Culper Research. (ECF No. 1- 2, 13). ? Count VIII for aiding and abetting was brought only against John Does. (ECF No. 1-2, p. 32).

(“Rule 12(b)(6)”). (ECF No. 6). For the following reasons, the Court will deny in part and grant in part Lamarco’s and Culper’s Motion to Dismiss. I. BACKGROUND A. Factual Background LifeMD is a Delaware corporation with its principal place of business in New York. (ECF No. 1-2, ¥ 8); (ECF No. 7, pp. 7, 9). Schreiber is an individual residing and domiciled in Puerto Rico. (ECF No. 1-2, 9). Galluppi is an individual residing and domiciled in California. (Jd. at 10). Lamarco is an individual residing and domiciled in Pennsylvania. (/d. at { 11). Culper is a limited liability company under the laws of Delaware. (/d. at { 12). LifeMD is a telehealth company that offers direct-to-patient products and services. (/d. at q 15). Specifically, it offers subscription-based products and services, including “REX MbD™— telehealth for men, Shapiro MD"™—telehealth for hair loss, and Nava MD™—teledermatology offering for women.” (/d. at J 16). It maintains a network of licensed medical providers and doctors who are board certified to treat patients and dispense prescription medications. (/d. at 19). LifeMD is managed by a team of professionals including Schreiber and Galluppi—-Schreiber serves as LifeMD’s Chairman and CEO while Galluppi serves as Chief Technology Officer. (Ud. at § 21). Culper is an independent stock research firm that conducts investment analysis and disseminates its reports via its website, www.culperresearch.com. (Ud. at | 12). On or about April 14, 2021, Culper published a negative report about LifeMD entitled LifeMD, Inc.: Redwood Redux at RexMD (“Report”), which appeared on its website www.culperresearch.com and via Twitter using the handle @CulperResearch. (Jd. at { 29). On the first page of the Report, Culper provided a disclaimer that included the following statement:

You should assume that Culper (possibly along with or through our members, partners, affiliates, employees, and/or consultants) along with our clients and/or investors has a position in any securities covered herein. Following publication of any research, we intend to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation, conclusions, or opinions. (ECF No. 1-2, p. 38). The disclaimer then proceeds to state that the Report comprises the author’s opinions: To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the securities covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. However, such information is presented “as is,” without warranty of any kind — whether express or implied. Culper makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Research may contain forward-looking statements, estimates, projections, and opinions with respect to among other things, certain accounting, legal, and regulatory issues the issuer faces and the potential impact of those issues on its future business, financial condition and results of operations, as well as more generally, the issuer’s anticipated operating performance, access to capital markets, market conditions, assets and liabilities. Such statements, estimates, projections and opinions may prove to be substantially inaccurate and are inherently subject to significant risks and uncertainties beyond Culper’s control. All expressions of opinion are subject to change without notice, and Culper does not undertake to update or supplement this report or any of the information contained herein. (/d.) (emphasis added). LifeMD alleges that Lamarco, Culper, and John Does engaged in an abusive “short and distort” stock scheme. (/d. at 1). A “short and distort” stock scheme occurs when “short-sellers borrow securities, sell them, and then drive the price of their target company’s stock down by spreading materially false, misleading, defamatory, and disparaging information about the company. Once the company’s stock drops to an artificially low price, the short-sellers repurchase and return the borrowed securities, pocketing the difference.” (/d.).

B. The Alleged Defamatory Communications In their Complaint, Plaintiffs allege the communications in the Report “falsely accused Plaintiffs of fraud, lies, cover-ups, potential crimes and illegal acts, insider dealing, and abusive, unfair, and deceptive business practices.” (Ud at § 3). Plaintiffs also allege that the communications caused significant harm, including: artificial depression of LifeMD’s stock price and market value; higher costs of capital; expenses to defend against class action lawsuits and negative media attention; damage to business relationships with contractual partners, investors, bankers, and other lenders; injury to Plaintiffs’ reputation and goodwill; emotional pain, suffering, and humiliation for the individual Plaintiffs; and disruption of the business affairs of Life which continues to this day as Plaintiffs seek to attract investors, recruit talent, and form strategic partnerships. (Id. at 94). The alleged defamatory communications are as follows: a. Redwood Scientific. “Importantly, Life MD executives - including CEO Justin Schreiber, CTO Stefan Galluppi, and the Company’s two former CFOs - have apparently covered up their involved [sic] in Redwood Scientific’s “wide ranging fraud’, which we think LifeMD now mirrors.” Report at 2. “Undisclosed to current LifeMD investors, numerous LFMD insiders were intimately involved in varying aspects of Redwood [Scientific]’s “wide-ranging fraud.’” Id. “We are highly concerned that LifeMD executives have not disclosed their involvement in material fraud, namely in Redwood Scientific, prior to joining LifeMD. We find this especially concerning in light of the business practices we believe are occurring at LifeMD which mirror those that landed Redwood federal charges.” Jd. at 3.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

New York Times Co. v. Sullivan
376 U.S. 254 (Supreme Court, 1964)
Gertz v. Robert Welch, Inc.
418 U.S. 323 (Supreme Court, 1974)
Milkovich v. Lorain Journal Co.
497 U.S. 1 (Supreme Court, 1990)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Ala, Inc. v. Ccair, Inc.
29 F.3d 855 (Third Circuit, 1994)
DiCarlo v. St. Mary Hospital
530 F.3d 255 (Third Circuit, 2008)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
O'MALLEY v. Vilsmeier Auctions Co.
986 F. Supp. 306 (E.D. Pennsylvania, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
LIFEMD, INC v. LAMARCO, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lifemd-inc-v-lamarco-pawd-2022.